Arun A Azad

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final totale...

Lancet (London, England) · 2 augustus 2025

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final totale overleving re...

Lancet (London, England) · 2 augustus 2025

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label,...

The Lancet. Oncology · 2025-07

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostat...

The Lancet. Oncology · 2025-04

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant...

The Lancet. Oncology · 2025-04

Talazoparib plus enzalutamide bij mCRPC: TALAPRO-2 veiligheid

European journal of cancer (Oxford, England : 1990) · 2024-12

Sequentieel Lu-PSMA-617 plus docetaxel versus docetaxel bij mHSPC: UpFrontPSMA fase II

The Lancet. Oncology · 2024-10

OS met Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP definitieve OS

The Lancet. Oncology · 2024-01

Talazoparib plus enzalutamide bij eerstelijns mCRPC: TALAPRO-2 fase III

Lancet (London, England) · 22 juli 2023

PSMA-PET en FDG-PET als biomarkers bij Lu-PSMA-617 versus cabazitaxel: TheraP analyse

The Lancet. Oncology · 2022-11

MEDI0680 plus durvalumab versus nivolumab bij mRCC: fase II

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 juli 2022

Enzalutamide en overleving bij mHSPC: ENZAMET definitieve OS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 mei 2022

[177Lu]Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP fase II

Lancet (London, England) · 27 februari 2021

Optimale sequentiëring van enzalutamide en abiraterone bij mCRPC

The Lancet. Oncology · 2019-12

Circulerend tumor-DNA en resistentie tegen abiraterone en enzalutamide bij prostaatcarcinoom

Cancer discovery · 2018-04